TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05363891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrunix
Description: Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrunix
Description: Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04299945

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: concentrated beetroot juice (400mg of nitrate per serving)
Description: Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: concentrated beetroot juice (trace amounts of nitrate per serving)
Description: Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
Study: NCT06444607

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Blood draw in the context of routine patient care, when a venipuncture is already scheduled.
Study: NCT05673811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
Study: NCT06444607

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Blood draw in the context of routine patient care, when a venipuncture is already scheduled.

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Blood draw in the context of routine patient care, when a venipuncture is already scheduled.

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Volunteering for blood draw.
Study: NCT05265689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bike Club
Description: Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bike Club Plus
Description: Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
Study: NCT04919811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taletrectinib
Description: 400mg or 600mg QD
Study: NCT06323941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery plus therapeutic exercise
Description: Isometric exercises (20 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: Isometric exercises (20 minutes) to which will be added a placebo motor imagery intervention (imagining a blue sky).
Study: NCT05673811

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
Study: NCT02720874

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rheumatoid arthritis educational booklet
Description: Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis educational booklet
Description: Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rheumatologic care
Description: At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse education and monthly calls
Description: Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly healthcare coordinator calls
Description: During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based symptom monitoring and reporting
Description: When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
Study: NCT05594264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBPStories
Description: The objective of this arm was to pilot test the web-based storytelling program to determine the preliminary impact on blood pressure and medication adherence, and if the web-based approach was an engaging approach for individuals managing hypertension.
Study: NCT06374758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Accelerate model of care
Description: Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
Description: Same as above, it is the same intervetion
Study: NCT05873829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-foot exercises
Description: Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
Study: NCT05328934

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SoftHand Pro
Description: Performance assessments utilizing the SoftHand Pro over an 8-week period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoftHand Pro
Description: Performance assessments utilizing the SoftHand Pro over an 8-week period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ossur i-Limb
Description: Performance assessments utilizing the i-Limb over an 8-week period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur i-Limb
Description: Performance assessments utilizing the i-Limb over an 8-week period.
Study: NCT05933395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
Study: NCT06211478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E will be taken for 6 months for gaucher disease patients who have oxidative stress and vitamin E defecient
Study: NCT05408949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single exercise into pain (SEP) program
Description: * Baseline assessment \& commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Initial follow-up \& progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Second follow-up \& progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~* Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~* Functional rehabilitation program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Symptom Modification Procedure (SSMP)
Description: \[1\] Finger on the sternum,\[2A\] Scapula modification \[3\] 'Humeral head' modification \[4\] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Rehabilitation Program
Description: Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
Study: NCT03863288

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Functional MRI (fMRI)
Description: Functional MRI (fMRI) scan with affective/cognitive tasks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI (fMRI)
Description: Functional MRI (fMRI) scan with affective/cognitive tasks
Study: NCT05436522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
Study: NCT05408949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Rehabilitation Program
Description: Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
Study: NCT03863288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI (fMRI)
Description: Functional MRI (fMRI) scan with affective/cognitive tasks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI (fMRI)
Description: Functional MRI (fMRI) scan with affective/cognitive tasks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI (fMRI)
Description: Functional MRI (fMRI) scan with affective/cognitive tasks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Intranasal Spray 8 International Unit (8IU)
Description: Oxytocin intranasal spray liquid administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin intranasal spray 24 International Unit (24IU)
Description: Oxytocin intranasal spray liquid administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin intranasal spray 48 International Unit (48IU)
Description: Oxytocin intranasal spray liquid administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin intranasal spray 80 International Unit (80IU)
Description: Oxytocin intranasal spray liquid administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal spray liquid administration
Study: NCT06364891

Intervention type: OTHER
Group type: OTHER
Intervention: VMMC NEXUS Digital application
Description: A handheld digital application which supports segmentation of potential VMMC Clients

Intervention type: OTHER
Group type: OTHER
Intervention: VMMC NEXUS Digital application
Description: A handheld digital application which supports segmentation of potential VMMC Clients
Study: NCT06249555

Intervention type: DRUG
Intervention: Vedolizumab (VDZ)
Description: Participants will receive VDZ as part of routine care.

Intervention type: DRUG
Intervention: Ustekinumab (UST)
Description: Participants will receive UST as part of routine care.

Intervention type: DRUG
Intervention: Risankizumab (RISA)
Description: Participants will receive RISA as part of routine care.
Study: NCT05132205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Radiofrequency Ablation using RFMedical device.
Study: NCT06398301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation Program
Description: A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals.
Study: NCT06159673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-204
Description: ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-204
Description: ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ACP-204 matching placebo
Study: NCT06449612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TeleRehaStroke: Training programme using the 'Blended Clinic' mobile application
Description: Primary end users (patients after stroke) will be familiarised with the application and the 'TeleRehaStroke' programme in two to three sessions during their last two to three weeks prior to discharge from the inpatient rehabilitation centre. This includes performing daily exercises, wearing an activity tracker and measuring blood pressure daily. Following discharge from rehabilitation, they will continue to use the application for 12 weeks.
Study: NCT06362018

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitopure (Urolithin A)
Description: Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure (Urolithin A)
Description: Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
Study: NCT05436522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
Study: NCT04110756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChangeGradients
Description: In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
Study: NCT06362018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure (Urolithin A)
Description: Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
Study: NCT05808608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
Study: NCT05291091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten 10 mg
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten 10 mg
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten 10 mg
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten 5 mg
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten 12.5 mg
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day
Study: NCT05985044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) Intervention
Description: The intervention consists of the following four components: i) needs assessment; ii) question prompt list; iii) goals discussion and; iv) symptom assessment and tracking. The intervention will start with the enrolment of a patient living with multimorbidity. The intervention consists of one in-person pre-discharge visit by the study team and four follow-up telephone calls (at 48 hours, 1 week, 4 weeks, and 6 weeks post-discharge).
Study: NCT05577858

Intervention type: OTHER
Group type: OTHER
Intervention: Meat based
Description: Omnivorous diet following dietary guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse based
Description: Lacto-ovo-vegetarian pulse-based diet following dietary guidelines